CD8A and neoplasm: In preclinical models, HMAs have been shown to increase the responses of tumor-specific CD8+ T cells through the upregulation of several epigenetically silenced tumor antigens and HLA and costimulatory molecules on the leukemic cell surface [28,29,30,31,32,33,34,35].